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Background: This study aimed to present our experience with
pulmonary metastasectomy in the treatment of hepatocellular carci-
noma and to evaluate the prognostic factors.
Methods: The clinicopathologic data of 17 patients including pres-
ence of viral hepatitis, the serum alpha-fetoprotein (AFP) level, the
number of metastases, and laterality were analyzed. The overall
survival rates and the prognostic factors were estimated using the
Kaplan-Meier method and Cox proportional hazards model for
multivariate analysis.
Results: The median follow-up periods after pulmonary resection
and initial hepatic resection were 28.9 and 46.2 months, respec-
tively. The actuarial overall 1-, 3-, and 5-year survival rates after
pulmonary metastasectomy were 64.7  11.6%, 29.4  11.1%, and
11.8  7.8%, respectively. Using multivariate analysis, disease-free
interval (DFI) of more than 24 months (hazard ratio  2.36, 95%
confidence interval  1.33–25.33, p  0.020) and AFP levels after
pulmonary resection (hazard ratio  51.3 95% confidence inter-
val  3.68–716.66, p  0.003) were found to be independent
prognostic factors.
Conclusions: Although only a small number of patients were
enrolled in this study, a disease-free interval more than 24 months
and the serum AFP level after pulmonary metastasectomy might be
important prognostic factors.
Key Words: Pulmonary metastasis, hepatocellular carcinoma, prog-
nostic factor.
(J Thorac Oncol. 2010;5: 1251–1254)
Hepatocellular carcinoma (HCC) is prevalent in Asia andis the third leading cause of cancer death in Korea.1 With
recent advances in diagnosis and treatment, an increasing
number of patients are eligible for hepatic resection at an
early stage and hepatic resection has been established as a
safe and an effective treatment modality. However, the long-
term prognosis of HCC remains unsatisfactory because of a
high incidence of tumor recurrence after hepatic resection.
Even though intrahepatic recurrence is more common than
extrahepatic recurrence, transarterial chemoembolization
(TACE), percutaneous ethanol injection and radiofrequency
ablation, and hepatic reresection or orthotopic liver transplan-
tation have improved the prognosis of HCC significantly.2–6
Unlike in case with intrahepatic metastasis, there is no defin-
itive treatment for HCC with extrahepatic metastasis although
some chemotherapeutic agents have been known to be effec-
tive in selective patients.7 In recent studies, pulmonary me-
tastasectomy has been found to improve long-term survival in
highly selective cases.8–10 However, because only a few cases
of pulmonary metastasectomy have been described, its role in
the treatment of pulmonary metastasis from HCC is still
unclear. Further, the indications and prognostic factors have
not yet been standardized. This study aimed to present our
experience with pulmonary metastasectomy from HCC and
evaluate the prognostic factors.
MATERIALS AND METHODS
Between January 1998 and December 2006, more than
400 patients with HCC underwent curative partial hepatec-
tomy in the Department of Surgery, Kyungpook National
University Hospital, Daegu, Korea. After hepatic resection,
the patients received followed up care at regular intervals of
3 months with physical examinations, biochemistry tests,
abdominal ultrasonographies, abdominal computed tomogra-
phies (CTs) to check for intrahepatic recurrence, and chest
radiographies to check for pulmonary metastasis. A chest CT
was performed when the chest radiograph showed abnormal-
ities. Among the patients who underwent hepatectomy, 37
patient developed pulmonary metastasis and 17 patients un-
derwent pulmonary resection. The selection criteria for pul-
monary resection were as follows: (1) no evidence of uncon-
trolled intrahepatic disease, (2) no evidence of extrathoracic
metastasis, (3) chest CT demonstrating that complete resec-
tion could be warranted regardless of the number of lesions,
and (4) tumors in the bilateral thorax not considered as a
contraindication. Similar to the patients who developed ad-
ditional pulmonary metastases after pulmonary resection,
further resection was performed according to the above-
mentioned criteria. Principally, wedge resection through tho-
racotomy was the procedure of choice although lobectomy
was performed when the metastatic lesion was located deep
in the pulmonary parenchyma. Lymph node dissection was
not undertaken.
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In each patient, clinicopathologic data were analyzed
retrospectively. The data included age, gender, presence of
viral hepatitis, and serum alpha-fetoprotein (AFP) level (at
prehepatic resection, immediately before and after pulmonary
resection). As for pulmonary factors, the number of patho-
logically confirmed metastases and laterality of metastasis
distribution were included. The disease-free interval (DFI)
comprised the period between the last curative treatment for
intrahepatic disease and the appearance of pulmonary metas-
tasis. The overall survival rates from pulmonary metastasec-
tomy were analyzed.
Statistical Methods
Survival was estimated by the Kaplan-Meier method.
The prognostic influence of variables on survival was ana-
lyzed using log-rank test for univariate analysis and the Cox
proportional hazards model for multivariate analysis. A value
of p less than 0.05 was regarded as significant. SPSS statis-
tical software version 14.0 (SPSS Inc., Chicago, IL) was used
for all statistical analyses.
RESULTS
Seventeen patients (14 men and 3 women) met the
criteria for pulmonary resection. Curative pulmonary resec-
tion was performed on all of them between January 1999 and
December 2007. Eleven patients were positive for the hepa-
titis B virus-related antigen, four patients were positive for
the hepatitis C antibody, and three were dual positive. The
AFP was high (100 ng/mL) in six patients and low (100
ng/ml) in 11 patients. Eight patients underwent TACE before
hepatic resection. The average mass size was 59 mm (range,
15–130 mm) and the average number of hepatoma was 1.5
(range, 1–3).
Six patients had hepatic recurrence before the discovery
of pulmonary metastases. All incidences of intrahepatic re-
currence were treated successfully by TACE or radiofre-
quency ablation. As a result, all patients had solitary or
resectable multiple pulmonary metastasis without uncon-
trolled hepatic disease. The median DFI between the hepa-
tectomy and appearance of pulmonary metastasis was 21.2
months (range, 4.9–50.1 months). The range of AFP serum
level before and after pulmonary metastasectomy was 2.0 to
780.6 and 1.3 to 6258 ng/ml, respectively. Wedge resection
was performed on 15 patients, whereas lobectomy was per-
formed on two patients. Ten patients had unilateral pulmo-
nary metastases and seven patients had bilateral metastases.
The mean number of pulmonary metastases was 3.8 (range,
1–17). The average size of pulmonary metastasis was 24.5
mm (range, 7–45 mm). There were no major complications
or operative mortality. The median follow-up for patients
after pulmonary resection and hepatectomy was 28.9 and 46.2
month, respectively. Only one patient was still alive without
disease and 16 patients died during the follow-up periods
(June 2009). The cause of death was disease related for all
patients. The median survival after the pulmonary resection
and the initial hepatic resection were 28.9 (range, 5.9–78.5)
and 46.2 (range, 12.8–106.7) months, respectively (Fig. 1A).
After pulmonary metastasectomy, recurrence was seen in 16
patients—pulmonary recurrence in 15 patients and intrahe-
patic recurrence in eight patients. The actuarial overall 1-, 3-,
and 5-year survival rates after pulmonary metastasectomy for
HCC were 64.7  11.6%, 29.4  11.1%, and 11.8  7.8%,
respectively (Fig. 1B).
Actuarial survival rates according to various clinical fac-
tors were determined by univariate analysis. Patients with high
AFP level before hepatic resection or after pulmonary metasta-
sectomy or who had a shorter DFI had inferior outcomes.
Patients who showed increasing AFP levels after pulmonary
metastasectomy also survived for a shorter time than those who
showed decreasing AFP levels (Table 1). From multivariate
analysis, only DFI (24 months, hazard ratio [HR] 2.36, 95%
confidence interval [CI]  1.33–25.33, p  0.020) and AFP
levels after pulmonary metastasectomy (HR  51.3 95% CI 
FIGURE 1. A, Overall survival after hepatectomy. B, Overall survival after pulmonary metastasectomy.
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3.68–716.66, p  0.003) were found to be independent predic-
tors of overall survival (Table 2).
DISCUSSION
Advances in surgical techniques and locoregional ther-
apy for HCC have resulted in better surgical outcomes and
long-term survival in recent years. However, the recurrence
rate after curative resection of HCC is high, with distant
metastasis most frequently found in the lung.11 Because local
control of intrahepatic recurrence has been undertaken in a
more proper and safe manner, there has been an increase in
the number of deaths resulting from respiratory failure from
pulmonary metastasis.12 Hence, active treatment for pulmonary
metastasis from HCC has received landmark clinical attention.
Although conducted on small number of patients, recent studies
have shown good results in selected cases.8–10,13 In our data, 3-
and 5-year survival rates were 29.4  11.1% and 11.8 7.8%,
respectively. These figures were higher than those treated non-
operatively. However, because the patients who were treated
conservatively had more extensive extrahepatic diseases or
poorer liver function, it is difficult to make a direct comparison
between surgical resection groups and the nonoperative group.
The favorable results in the surgical resection group could
undoubtedly reflect a selection bias in terms of tumor burden and
biology. To prevent any selection bias, Tominaru et al. com-
pared the resection group with the nonresection group with the
same clinicopathologic factors. In the resection group, the 3-year
survival rate after pulmonary metastasectomy for HCC was
33.3%, as compared with 0% in the nonresection group.9 In our
study, 20 patients with pulmonary metastasis from HCC did not
undergo pulmonary resection because these patients had more
extensive extrahepatic metastasis or were in poorer general
condition. Therefore, we could not compare these patients with
the resection group. Gwak et al.14 assumed that long-term
survival acquired by pulmonary metastasectomy might depend
on whether it was a reflection of a fate dictated by intrinsic tumor
biology. Therefore, we attempted to determine the prognostic
factors for patients who underwent pulmonary metastasectomy
for HCC. Until now, DFI10,13 and number of metastases have
been the accepted prognostic factors for pulmonary metastasec-
tomy for HCC.13 Also, AFP before pulmonary metastasec-
tomy,10 the size of pulmonary metastasis,15 or liver transplanta-
tion16 was reported to be prognostic factor (Table 3). A shorter
DFI indicated a more aggressive biology of the primary tumor
and ultimately determined poorer overall survival. In our results,
DFI (24 months) was significant independent prognostic fac-
tor in univariate and multivariate analyses (HR  2.36, 95%
CI  1.33–25.33, p  0.020). The efficacy of metastasectomy
for multiple lesions has generated controversy because even
after an apparently complete resection, most patients experience
recurrent pulmonary disease from undetected micrometastatic
disease present at the time of surgery. In this study, multiple
metastases were not a contraindication as long as respiratory
function could be preserved and complete resection could be
warranted. In our study, multiple metastases (more than two)
were not a significant factor for survival in univariate or multi-
variate analysis, because even patients with small number of
pulmonary metastases had intrapulmonary recurrence. In 1990,
the International Registry of PulmonaryMetastasis presented the
resectability, DFI more than 36 months, and single metastasis as
generally important prognostic factors.17 In addition to these
general prognostic factors, each pulmonary metastasis, for a
variety of histologies, might have its own prognostic factors. For
example, increase of preoperative carcinoembryonic antigen to
more than 200 ng/ml has been shown to be a negative prognostic
factor for survival in patients with colorectal cancer.18 In this
context, serumAFP level has been known as an important tumor
TABLE 1. Kaplan-Meier Analysis of Cancer-Specific Survival
Factor n
1-Yr
Survival
(%)
3-Yr
Survival
(%)
5-Yr
Survival
(%) p
AFP level, before HR 0.037
100 ng/ml 11 81.8 45.5 18.2
100 ng/ml 6 33.3 0 0
AFP level, before PM 0.420
100 ng/ml 9 88.9 44.4 11.1
100 ng/ml 7 42.9 14.3 0
AFP level, after PM 0.001
100 ng/ml 10 90.0 50.0 20.0
100 ng/ml 6 16.7 0 0
AFP level, follow-up 0.003
Before PM  after PM 8 87.5 50.0 25.0
Before PM  after PM 8 37.5 12.5 0
DFI (HR–PM) 0.002
24 mo 10 90.0 30.0 0
24 mo 7 85.7 85.7 57.1
AFP, alpha-fetoprotein; HR, hepatic resection; PM, pulmonary metastasectomy;
DFI, disease-free interval.
TABLE 2. Multivariate Analysis
Variables
Hazard
Ratio
95% Confidence
Interval p
Multiple pulmonary metastasis 2.36 0.554–10.063 0.245
Disease free interval (24 mo) 5.79 1.33–25.3 0.020
AFP level at pre-PM 0.23 0.03–1.83 0.166
AFP level at post-PM 51.32 3.68–716.66 0.003
AFP, alpha-fetoprotein; PM, pulmonary metastasectomy.
TABLE 3. Summary of References for Pulmonary
Metastasectomy of Hepatocellular Carcinoma
Study
No. of
Patients
5-Yr
Survival Prognostic Factors
Lam et al.8 9 67% —
Nakagawa et al.10 25 36% DFI 12 mo, AFP before
500 ng/ml
Kuo et al.13 34 27.5% DFI 12 mo, fewer PM 3
Chen et al.15 12 21.4% Tumor size 3 cm
Kwon et al.16 16 26% Liver transplantation
Our study 17 11.8% DFI 24 mo, AFP after PM
100 ng/ml
AFP, alpha-fetoprotein; PM, pulmonary metastasectomy; DFI, disease-free interval.
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marker for HCC and this marker might act as a prognostic
factor. Greater than 70% of HCC patients have a high serum
concentration of AFP because of the tumor excretion, and serum
AFP level is related to HCC cell differentiation.19 Patients with
serum AFP concentration more than 400 ng/ml had a poor
prognosis after hepatic resection.20 A high AFP level is a poor
prognostic factor not only in the metastastic stage but also in
several clinical features. AFP also plays a role in monitoring the
response to treatment in HCC. The current recommended strat-
egy for posttreatment follow-up combines imaging techniques
with the serum AFP assay. A fall in serum AFP concentration
with a half-time of less than 5 days and a normalization to an
AFP serum concentration to less than 10 ng/ml within 30 days
is one criterion to assess treatment effectiveness.21 In our study,
the serumAFP level (100 ng/mL) before hepatic resection was
a significant prognostic factor in univariate analysis using log-
rank test, although there was no significance in multivariate
analysis. We found a significant trend in the serum AFP level
after pulmonary metastasectomy. When the serum AFP level
after pulmonary metastasectomy was more than 100 ng/mL, the
1-year survival rate was 16.7%. This was lesser than that of
patients with serumAFP less than 100 ng/mL. Also, multivariate
analysis showed the serum AFP after pulmonary metastasec-
tomy was a significant factor (HR  51.3 95% CI  3.68–
716.66, p  0.003). These results are an indication that serum
AFP level is not only a tumor marker of HCC and a prognostic
factor of hepatic resection but also a good prognostic factor of
pulmonary metastasectomy for HCC.
In conclusion, DFI more than 24 months and serum
AFP level after pulmonary metastasectomy might be im-
portant prognostic factors for pulmonary metastasis from
HCC.
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